Sign In
Buy VYNE
$0.656
-0.0200 (-2.96%)
At Close: Jun 03, 2026
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
08:00am, Thursday, 08'th May 2025
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 Expected cash runway into 2H 2026 BRIDGEWATER, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VY
FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold
11:55am, Friday, 25'th Apr 2025
The U.S. Food and Drug Administration (FDA) on Friday verbally informed that it placed a clinical hold on VYNE Therapeutics Inc.'s VYNE Phase 1b study evaluating VYN202 for the treatment of moderate-t
VYNE Therapeutics Provides Update on VYN202 Program
08:00am, Friday, 25'th Apr 2025
BRIDGEWATER, N.J., April 25, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) verbally
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
08:00am, Thursday, 20'th Mar 2025
BRIDGEWATER, N.J., March 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differen
VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update
08:00am, Thursday, 06'th Mar 2025
Repibresib gel (VYN201) Phase 2b vitiligo top-line results expected in mid-2025 VYN202 Phase 1b psoriasis trial initiated with results anticipated by year-end 2025 Expected cash runway into 2H 2026 BR
VYNE Therapeutics to Participate in March Investor Conferences
08:00am, Thursday, 20'th Feb 2025
BRIDGEWATER, N.J., Feb. 20, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing different
VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis
08:00am, Wednesday, 19'th Feb 2025
BRIDGEWATER, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing different
VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo
07:30am, Monday, 06'th Jan 2025
BRIDGEWATER, N.J., Jan. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing different
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
07:30am, Monday, 23'rd Dec 2024
BRIDGEWATER, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing different
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
10:16am, Thursday, 07'th Nov 2024
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $1.85 per share a year ago.
VYNE Therapeutics Announces Positive Phase 1a SAD Data for VYN202, a Novel BD2-Selective BET Inhibitor
08:00am, Thursday, 12'th Sep 2024
BRIDGEWATER, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differen
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Tops Revenue Estimates
10:11am, Wednesday, 14'th Aug 2024
VYNE Therapeutics Inc. (VYNE) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $3.08 per share a year ago.
VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
08:00am, Wednesday, 14'th Aug 2024
BRIDGEWATER, N.J., Aug. 14, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing different
VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum
08:00am, Wednesday, 26'th Jun 2024
Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases Boston event to focus on Immunology & Inflammation (I&I) and Metabolic Diseases
VYNE Therapeutics Announces Dosing of First Participants in Phase 1a Trial of Novel BD2-Selective BET Inhibitor VYN202
09:02am, Thursday, 13'th Jun 2024
VYN202 has been designed to achieve class-leading potency and BD2-selectivity Trial will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of VYN202 in healthy volunteers; top-line
